MedTrace Logo

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

NCT00544557 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1715

Last updated 2015-05-12

Study results available
· View outcomes & findings →

Summary

This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.

Conditions

Interventions

DRUG

Etanercept

The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544557 on ClinicalTrials.gov